In a phase II clinical trial of NSCLC patients treated with nab-paclitaxel, Cav-1 expression in CAFs was related to prolonged survival and increased response rates, indicating that Cav-1 is a marker of nab-paclitaxel treatment efficacy [224]. The gene discussed is CAV1; the disease is non-small cell lung carcinoma.